Scenarios | MDA type | MDA coverage | VC coverage |
|---|
MDA1 | Annual | CC | CC |
MDA2 | Annual | CC | 80% |
MDA3 | Annual | 80% | CC |
MDA4 | Annual | 80% | 80% |
Bi-MDA1 | Biannual | CC | CC |
Bi-MDA2 | Biannual | CC | 80% |
Bi-MDA3 | Biannual | 80% | CC |
Bi-MDA4 | Biannual | 80% | 80% |
IDA1 | Annual | CC | CC |
IDA2 | Annual | CC | 80% |
IDA3 | Annual | 80% | CC |
IDA4 | Annual | 80% | 80% |
- MDA-based LF interventions were simulated for the following 12 intervention scenarios where MDA represents the standard two-drug regimen (diethylcarbamazine-albendazole) delivered annually, Bi-MDA represents the standard two-drug regimen delivered biannually, and IDA represents a triple-drug regimen (ivermectin-diethylcarbamazine-albendazole) delivered annually. Each type of MDA is combined with vector control (VC) at either current (CC) or enhanced (80%) coverage
